The species on the label is the first thing a reagent buyer chooses and the last thing they usually think about. It decides the reagent's activity, its antibody background, its contaminant risk and its regulatory paperwork. Where the animals came from decides how consistent the next lot will be. Here's how we think about both.
Choosing the species
Start with activity, because the same protein doesn't behave the same way across species. Young rabbit complement lyses far more efficiently than guinea pig or human complement, which is why it's the reference source for bactericidal assays. The tissue source of a thromboplastin sets its sensitivity index. Bovine albumin blocks a membrane as well as human albumin at a fraction of the price. Published assays usually specify a species, and changing it means re-validating.
Antibody background comes next. An adult animal's serum carries antibodies to everything it has met. For a complement source or a blocking serum that matters. Baby rabbits are used precisely because at 3 to 4 weeks they haven't yet acquired antibodies to human pathogens, and human serum has to be antibody-depleted before it can play the same role.
Cross-reactivity with the sample is next. A secondary antibody or a blocking serum should come from a species distant from the sample, so anti-species reagents don't light up the sample's own immunoglobulin. Goat and donkey products exist largely for this reason.
Contaminant risk is the third factor. Species differ in the adventitious agents they can carry, and regulators treat animal-derived materials accordingly. The FDA's guidance on cell substrates and other biological materials used in vaccine production, for example, expects animal-derived raw materials to be qualified for adventitious agents, with particular attention to bovine and porcine sources and transmissible spongiform encephalopathies (FDA). For research use that comes down to knowing the herd, the country of origin and the health testing behind a lot.
Why the animals matter as much as the species
Once the species is fixed, lot-to-lot consistency comes from the animals. Age changes hormone levels, antibody titers and complement activity; diet changes lipid; stress at collection changes hemolysis and cortisol; and disease exposure changes everything. Reagents collected from animals of mixed and unknown history vary in ways no release test fully captures. The WHO's good manufacturing practice for biological products devotes a section to the use of animals for exactly this reason, requiring that production animals be of defined health status, monitored, housed under controlled conditions and documented (WHO). Research reagents aren't held to GMP, but the logic carries over.
How we source
Our rabbits are raised in our own colony in Arkansas, on a controlled diet and under a written animal-welfare program (see our animal welfare commitments). Blood is collected and rabbit blood products and tissues are processed on site, so for every rabbit lot the age class, health history and collection date are known and recorded. Other species come from established suppliers with documented herd health and country of origin, and human material comes from FDA-licensed collection centers with donor screening and testing. Where the species or age class matters to your assay, it appears in the product name so you're choosing it deliberately.
If you're selecting a species for a new assay, or need documentation on the origin of the animals behind a lot for a qualification file, contact us. We can tell you what other laboratories running the same assay have chosen and what origin documentation we can supply.